e-learning
resources
London 2016
Wednesday, 07.09.2016
Cystic fibrosis: inflammation, microbiology, management and monitoring
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Use of national disease registries in the conduct of long-term post-authorisation drug safety studies (LTSSs)
Diana Bilton (Huntingdon, United Kingdom), Diana Bilton, Noreen Caine, Rebecca Cosgriff, Stephen Nyangoma, Siobhan Carr
Source:
International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Session:
Cystic fibrosis: inflammation, microbiology, management and monitoring
Session type:
Poster Discussion
Number:
4868
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Diana Bilton (Huntingdon, United Kingdom), Diana Bilton, Noreen Caine, Rebecca Cosgriff, Stephen Nyangoma, Siobhan Carr. Use of national disease registries in the conduct of long-term post-authorisation drug safety studies (LTSSs). Eur Respir J 2016; 48: Suppl. 60, 4868
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: What’s NEW in the 2022 ERS/ATS PFT Interpretation Statement
Cystic fibrosis and intestinal organoids
Clinics of Cystic Fibrosis Patients with Unusual Bacteria Isolated fromRespiratory Cultures
Related content which might interest you:
Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases)
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort
Source: International Congress 2016 – The best is yet to come in terms of lung function
Year: 2016
Interim analysis of the EXCITING-ILD registry
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Pirfenidone post-authorization safety registry (PASSPORT) update
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development
Source: Eur Respir J 2007; 29: 582-586
Year: 2007
CF-ABLE-UK score: Modification and validation of a clinical prediction rule for prognosis in cystic fibrosis on data from UK CF registry
Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous
Year: 2015
Respiratory effects of cannabis smoking: A literature review
Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD
Year: 2016
Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting
Source: International Congress 2014 – ILDs 6
Year: 2014
PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Polish Spirometry Day 2013 as a way to increase public awareness concerning the causes, course and consequences of chronic respiratory diseases
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014
Incidence and prevalence of IPF in an insurance claims database: Assessing accuracy using medical records
Source: International Congress 2014 – Respiratory disease within hospital-based populations
Year: 2014
Paediatric pulmonary hypertension: monitoring progress and identifying unmet needs
Source: Eur Respir Rev 2009; 18: 18-23
Year: 2009
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
Clinical use of interstitial lung disease guidelines
Source: Eur Respir Mon; 2009: 46: 386–395
Year: 2009
Recruiting to telehealth has a role during discharge planning in COPD: A feasibility and acceptability study
Source: Annual Congress 2013 –The latest insights in chronic care
Year: 2013
The quality of evidence-based clinical practice guidelines for chronic respiratory diseases could be improved: An observational study
Source: International Congress 2016 – Treatment and assessment of functional outcomes in cardiorespiratory physiotherapy
Year: 2016
Translating research into practice: how are guidelines implemented?
Source: Eur Respir J 2003; 21: 23S-29S
Year: 2003
Collating data from major European population studies – The CADSET (Chronic airway disease early stratification) clinical research collaboration
Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases
Year: 2020
European COPD Audit: design, organisation of work and methodology
Source: Eur Respir J 2013; 41: 270-276
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept